SAM
IHE icon

Strive Asset Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Strive Asset Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,846
Closed -$201K – 93
2025
Q1 		$201K Sell
2,846
-1,103
-28% -$76.7K 0.14% 115
2024
Q4 		$260K Buy
+3,949
New +$272K 0.19% 106

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Strive Asset Management's IHE Position: Q2 2025 in Review

Strive Asset Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2025, closing a stake of 2,846 shares — an estimated $201K sold.

Strive Asset Management first reported a position in IHE in Q4 2024 and held it in 2 quarters. The position peaked at $260K in Q4 2024. 139 funds tracked by Wall St. Rank hold IHE as of Q2 2025.

  • Strive Asset Management reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2025 after selling out during the quarter.
  • Strive Asset Management sold 2,846 iShares US Pharmaceuticals ETF shares in Q2 2025, an estimated $201K.
  • Strive Asset Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2024 and held it in 2 quarters.
  • Strive Asset Management's iShares US Pharmaceuticals ETF position peaked at $260K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2025.

Based on Strive Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.